Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis von Alicandro, G., Orena, B.S., Rosazza, C., Cariani, L., Russo, M., Zatelli, M., Badolato, R., Gramegna, A., Blasi, F., Daccò, V.

Volltext

Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes von Grancini, V., Alicandro, G., Porcaro, L. L., Zazzeron, L., Gramegna, A., Morlacchi, L. C., Rossetti, V., Gaglio, A., Resi, V., Daccò, V., Blasi, F., Orsi, E.

Volltext

Risk of CFTR-related disorders and cystic fibrosis in an Italian cohort of CRMS/CFSPID subjects in preschool and school age von Fevola, C., Dolce, D., Tosco, A., Padoan, R., Daccò, V., Claut, L., Schgor, T., Sepe, A., Timpano, S., Fabrizzi, B., Piccinini, P., Taccetti, G., Bonomi, P., Terlizzi, V.

Volltext

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion von Colombo, C., Foppiani, A., Bisogno, A., Gambazza, S., Daccò, V., Nazzari, E., Leone, A., Giana, A., Mari, A., Battezzati, A.

Volltext

P174 Effects of proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: a matched cohort study von Sciarrabba, C.S., Zazzeron, L., Lanfranchi, C., Bulfamante, A.M., Dacco’, V., Alicandro, G., Colombo, C.

Volltext

P160 Effects of elexacaftor/tezacaftor/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis related diabetes von Zazzeron, L., Gramegna, A., Grancini, V., Bulfamante, A.M.C., Piedepalumbo, F., Lanfranchi, C., Dacco, V., Orsi, E., Blasi, F.B.A.

Volltext

P153 An Italian centre experience with elexacaftor/tezacaftor/ivacaftor therapy in 6 to 11 year olds with cystic fibrosis von Rosazza, C., Alicandro, G., Zazzeron, L., Russo, M., Claut, L.E., Rizza, C., Sciarrabba, C.S., Blasi, F.B.A., Dacco, V.

Volltext

P155 The impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on occurrence of bacterial lung infections in cystic fibrosis patients von Cariani, L., Alicandro, G., Teri, A., Girelli, D., Orena, B.S.O., Liporace, M.F., Zatelli, M., Ceriotti, F., Blasi, F.B.A., Dacco, V.

Volltext

Epidemiology of Chronic Renal Failure in Children: Data From the ItalKid Project von Ardissino, Gianluigi, Dacco, Valeria, Testa, Sara, Bonaudo, Roberto, Claris-Appiani, Aldo, Taioli, Emanuela, Marra, Giuseppina, Edefonti, Alberto, Sereni, Fabio

Volltext

Spontaneous hypoglycemia in patients with cystic fibrosis von Battezzati, A, Battezzati, P M, Costantini, D, Seia, M, Zazzeron, L, Russo, M C, Daccò, V, Bertoli, S, Crosignani, A, Colombo, C

Volltext

ePS4.06 Antibody response to administration of 2 doses of the BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis von Alicandro, G., Dacco’, V., Cariani, L., Contarini, M., Rosazza, C., Sciarrabba, C.S., Ferraro, F., Orena, B.S., Colombo, C.

Volltext

Analysis of Inflammatory and Immune Response Biomarkers in Sputum and Exhaled Breath Condensate by a Multi-Parametric Biochip Array in Cystic Fibrosis von Colombo, C., Faelli, N., Tirelli, A.S., Fortunato, F., Biffi, A., Claut, L., Cariani, L., Daccò, V., Prato, R., Conese, M.

Volltext

Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor von Terlizzi, Vito, Fevola, Cristina, Presti, Santiago, Castaldo, Alice, Daccò, Valeria, Claut, Laura, Sepe, Angela, Majo, Fabio, Casciaro, Rosaria, Esposito, Irene, Vitullo, Pamela, Salvi, Marta, Troiani, Patrizia, Ficili, Francesca, Parisi, Giuseppe Fabio, Pantano, Stefano, Costa, Stefano, Leonetti, Giuseppina, Palladino, Nicola, Taccetti, Giovanni, Bonomi, Paolo, Salvatore, Donatello

Volltext

223 Analysis of “cost drivers” for health care services use in cystic fibrosis patients: the experience of the Milan Cystic Fibrosis Center von Colombo, C, Daccò, V, Loi, S, Anelli, M, Alicandro, G

Volltext

No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy—report from the ItalKid Project database von Ardissino, Gianluigi, Viganò, Sara, Testa, Sara, Daccò, Valeria, Paglialonga, Fabio, Leoni, Antonio, Belingheri, Mirco, Avolio, Luigi, Ciofani, Antonio, Claris-Appiani, Aldo, Cusi, Daniele, Edefonti, Alberto, Ammenti, Anita, Cecconi, Milva, Fede, Carmelo, Ghio, Luciana, La Manna, Angela, Maringhini, Silvio, Papalia, Teresa, Pela, Ivana, Pisanello, Lorena, Ratsch, Ilse Maria

Volltext

705 Cystic fibrosis mortality trends in countries where people cannot access elexacaftor/tezacaftor/ivacaftor therapy von Alicandro, G., Zazzeron, L., Vecchia, C. La, Daccò, V.

Volltext

632 Change in insulin secretion and sensitivity in people with cystic fibrosis and negative history for diabetes after 6 months of elexacaftor/tezacaftor/ivacaftor therapy von Daccò, V., Zazzeron, L., Alicandro, G., Grancini, V., Orsi, E., Cogliati, I.

Volltext

618 Long-term monitoring of liposoluble vitamins in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor therapy von Zazzeron, L., Alicandro, G., Bulfamante, A., Russo, M., Bellante, F., Visciola, V., Daccò, V.

Volltext

574 Effects on metabolic control and body composition of insulin therapy optimization with sensor-augmented pump in people with cystic fibrosis–related diabetes von Zazzeron, L., Grancini, V., Alicandro, G., Gramegna, A., Morlacchi, L., Bulfamante, A., Daccò, V., Blasi, F.

Volltext

718 Lung clearance index decreases in patients who do not achieve clinically meaningful improvement in ppFEV1 after elexacaftor-tezacaftor-ivacaftor therapy von Nazzari, E., Alicandro, G., Zazzeron, L., Rosazza, C., Rizza, C., Gramegna, A., Blasi, F., Daccò, V.

Volltext